The Lynx Group

Rectal Cancer

First-line treatment with dostarlimab-gxly (Jemperli), a PD-1 inhibitor, achieved complete responses (CRs) in 100% of a subset of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, sparing them surgery, chemotherapy, and radiation, as of the latest follow-up.
Read Article


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: